Nationwide Fund Advisors Boosts Stake in Celgene Co. (CELG)

Nationwide Fund Advisors raised its stake in shares of Celgene Co. (NASDAQ:CELG) by 2.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 778,880 shares of the biopharmaceutical company’s stock after purchasing an additional 15,211 shares during the quarter. Celgene accounts for about 0.4% of Nationwide Fund Advisors’ investment portfolio, making the stock its 24th biggest position. Nationwide Fund Advisors owned about 0.10% of Celgene worth $113,576,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Schmidt P J Investment Management Inc. bought a new stake in Celgene in the third quarter valued at about $221,000. Personal Capital Advisors Corp increased its stake in Celgene by 5.9% in the third quarter. Personal Capital Advisors Corp now owns 188,252 shares of the biopharmaceutical company’s stock valued at $27,451,000 after acquiring an additional 10,419 shares during the period. Fox Run Management L.L.C. bought a new stake in Celgene in the third quarter valued at about $860,000. Swedbank increased its stake in Celgene by 1.1% in the third quarter. Swedbank now owns 2,621,252 shares of the biopharmaceutical company’s stock valued at $382,231,000 after acquiring an additional 27,372 shares during the period. Finally, CAPROCK Group Inc. increased its stake in Celgene by 8.0% in the third quarter. CAPROCK Group Inc. now owns 6,044 shares of the biopharmaceutical company’s stock valued at $881,000 after acquiring an additional 446 shares during the period. Institutional investors own 79.84% of the company’s stock.

Celgene Co. (NASDAQ:CELG) opened at $106.33 on Friday. Celgene Co. has a 12-month low of $94.55 and a 12-month high of $147.17. The stock has a market cap of $84,940.00, a P/E ratio of 25.08, a PEG ratio of 0.84 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the prior year, the business earned $1.58 earnings per share. Celgene’s quarterly revenue was up 10.2% on a year-over-year basis. research analysts anticipate that Celgene Co. will post 6.68 EPS for the current fiscal year.

CELG has been the topic of a number of analyst reports. Vetr cut shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 target price on the stock. in a research note on Tuesday, August 29th. Royal Bank of Canada lowered their target price on shares of Celgene from $166.00 to $148.00 and set a “top pick” rating on the stock in a research note on Friday, October 27th. Leerink Swann reissued a “buy” rating and issued a $156.00 target price on shares of Celgene in a research note on Friday, October 20th. Morgan Stanley reduced their price target on shares of Celgene from $120.00 to $115.00 and set an “underweight” rating on the stock in a research report on Monday, October 23rd. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Celgene in a research report on Monday, August 28th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $135.43.

In related news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.95% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/23/nationwide-fund-advisors-boosts-stake-in-celgene-co-celg.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit